Skip to Content
US Videos

Drugmakers and Managed-Care Firms Are Poised for Growth

These areas remain undervalued even though valuations for the overall healthcare sector look a bit high.

Mentioned: , ,

Damien Conover: Looking at the healthcare sector today, and one of the areas where we've seen some nice performance, the group is up almost 30% over the last 12 months. While that's been pretty strong performance, the overall market is up almost 50%. So, there's a little bit of underperformance in healthcare relative to the overall market. And we think a lot of that has to do with potential concerns around new U.S. policies that could hurt drug-pricing power and could potentially hurt some of the managed-care organizations. But when we take a look at overall valuation right now, we think the overall healthcare space looks like it's largely fairly valued to slightly overvalued. But again, the two areas that we think have the most interest are the drug manufacturers and managed-care sectors because of this concern around potential U.S. healthcare policy reforms.

Going forward, as we look ahead, we think both groups look well positioned for growth, and we think only moderate policy change will happen, largely because the Democrats only control a slight majority in the senate. And healthcare policy reform is very complex, and we don't think it will happen rapidly or to a huge extent. As we think about the quarter ahead, we do think there's going to be some normalization coming back into the overall healthcare landscape, which we think is particularly important for any healthcare industry that's more elective in nature. So, areas like dental, devices, even some hospital elective procedures, they all should start to rebound, and we're forecasting herd immunity in the United States by the middle point of the summer. Potentially even earlier, depending on how fast the vaccine rollout can happen.

Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.